NVSNovartis PharmaceuticalsRunning, no new patients
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Myelodysplastic Syndromes · Leukemia, Myelomonocytic, Chronic
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 33 (final count)
- Started
- Feb 28, 2023
- Main results expected
- Feb 14, 2028
- Fully finished
- Feb 14, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over: 5 years
Severity of AEs and SAEs
Measured over: 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05201066 · record last updated 2026-09-22 · checked 2026-11-09 15:47 UTC